Prescription Medicines
Nasopra Tab. 500/20mg
- Product Category
- Analgesics, Antipyretics & Anti-inflammatory Medicines
- Active Ingredients
- Naproxen, esomeprazole
- Appearance
- Biconvex, oval-shaped, yellow film-coated tablet consisting of a core and an outer core.
- Reimbursement Code
- 648105180
01 / 03
1. Composition and Strength : 1 tablet (730.5 mg) of this medicine
- Active ingredient: Naproxen (USP) · · · · · · · 500mg
Esomeprazole Magnesium Trihydrate (USP) · · · · · · · 22.3mg (20mg as Esomeprazole)
- Additives: 30% dispersion of methacrylic acid/ethyl acrylate copolymer (1:1), titanium oxide, magnesium stearate, opadry yellow (03B62519), precipitated calcium carbonate, carnauba lead, colloidal silicon oxide, croscarmellose sodium, triethyl citrate, povidone, Polysorbate 80, polyethylene glycol 6000, plastic acrylic tea 20, hypromellose
2. Effectiveness
Treatment of symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients who are at risk of developing gastric and/or duodenal ulcers related to non-steroidal anti-inflammatory drugs (naproxen, etc.) and who are not adequately treated with low-dose naproxen or other non-steroidal anti-inflammatory drugs.
3. Dosage and dosage
Adults: Administer orally twice a day, 1 tablet each time (naproxen 500mg/esomeprazole 20mg).
Do not split, chew, or crush this medicine; swallow it as is with water. It is recommended to take it at least 30 minutes before a meal.
4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.
2) Cardiovascular risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious cardiovascular thrombotic reactions, myocardial infarction and stroke, which can be fatal. This risk may occur as early as the first week of treatment and may increase with duration of treatment. An increased risk of cardiovascular thrombosis was consistently observed at higher doses. Patients with cardiovascular disease (e.g., uncontrolled hypertension, congestive heart failure, ischemic heart disease, peripheral artery disease, and/or cerebrovascular disease) and patients with risk factors for cardiovascular disease (e.g., hypertension, hyperlipidemia, diabetes, and smoking) may be at greater risk and should be treated with this drug after careful consideration. Physicians and patients must carefully monitor the development of these cardiovascular symptoms, even if there is no history of cardiovascular disease. Patients should be informed in advance about signs and/or symptoms of serious cardiovascular toxicity and what measures to take if these symptoms occur.
3) Gastrointestinal risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious gastrointestinal adverse reactions, including gastric or intestinal bleeding, ulceration, and perforation, which may be fatal. Compared to naproxen administered alone, this drug significantly reduced the occurrence of gastric ulcers, but ulcers and related complications still occur. These adverse reactions may occur without warning symptoms during the administration period. Older adults may be at greater risk for serious gastrointestinal adverse events.
The longer the administration period, the more likely it is that serious gastrointestinal side effects will occur, but this risk cannot be completely ruled out during short-term administration.
While administering this drug, patients should be carefully monitored for symptoms and signs of gastrointestinal ulcers or bleeding, and if serious adverse gastrointestinal reactions are suspected, additional evaluation and treatment should be performed immediately. Discontinuing the administration of non-steroidal anti-inflammatory drugs until severe gastrointestinal side effects are completely ruled out can also be a treatment option. For patients at high risk, alternative treatments unrelated to NSAIDs should be considered.
2. Do not administer to the following patients.
1) Patients with hypersensitivity to naproxen, esomeprazole, substituent benzimidazole, and other components of this drug
2) Patients with asthma, rhinitis, nasal polyps, urticaria, allergic reactions or a history of such reactions due to administration of aspirin or other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors) (In these patients, severe and fatal anaphylactoid reactions have been rarely reported after administration of non-steroidal anti-inflammatory drugs).
3) Patients with active peptic ulcer
4) Patients with gastrointestinal bleeding, cerebrovascular hemorrhage, other bleeding diseases, and patients with severe blood abnormalities
5) Patients with severe hepatic impairment (e.g. Childs-Pugh class C)
6) Patients with severe heart failure
7) Patients with severe renal impairment (creatinine clearance less than 30mL/min)
8) Patients with severe high blood pressure
9) Treatment of pain occurring before and after coronary artery bypass surgery (CABG)
10) Pregnant women in the last 3 months of pregnancy
11) Patients receiving atazanavir, nelfinavir
12) Patients taking rilpivirine-containing preparations (see 「6. Interactions」)
3. Administer with caution to the following patients.
1) Patients with a history of peptic ulcer
2) Patients with blood abnormalities or their history
3) Patients with bleeding tendencies (platelet function decline may occur.)
4) Patients with hepatic impairment or its history
5) Patients with renal impairment or its history and patients with reduced renal blood flow
6) Patients with cardiac dysfunction
7) Patients with high blood pressure
8) Patients with a history of hypersensitivity
9) Patients with bronchial asthma
10) Patients with induced porphyria, patients with systemic lupus erythematosus (SLE), and patients with mixed connective tissue disease (MCTD)
11) Elderly people
4. Adverse reactions
1) As a result of comparing the safety data of the group administered this drug (n=1157) and the main ingredients of this drug, naproxen and esomeprazole, there was no newly added safety information.
2) In clinical trials, adverse reactions that occurred when administering this drug were classified according to frequency and organ of occurrence (SOC; System Organ Class) as follows. Frequency is defined as follows: Very common (>1/10), common (>1/100, <1/10), uncommon (>1/1,000, <1/100), rare (>1/10,000, <1/1,000), very rare (<1/10,000), unknown (not measured in available data)
※ Table: Refer to attached document
*Confirmed by planned routine endoscopy.
3) Adverse reactions in clinical trials and post-marketing surveillance of naproxen are as follows.
① Hypersensitivity: Shock symptoms (difficulty breathing, lowered blood pressure, bradycardia, cold sweat, edema, etc.), PIE syndrome (pulmonary infiltration accompanied by eosinophilia: accompanied by fever, wheezing, cough, and phlegm), anaphylactoid reaction, hives, rash, itching, etc.
② Digestive system: Hematemesis, gastrointestinal bleeding, peptic ulcer, perforation, stomach discomfort, stomach pain, abdominal pain, nausea, vomiting, loss of appetite, indigestion, heartburn, diarrhea, constipation, stomatitis, abdominal bloating, black stool, dry mouth, esophagitis, gastritis, glossitis, eructation, flatulence, melanosis, pancreatitis, colitis, worsening of inflammatory bowel disease (ulcerative colitis, Crohn's disease), Rectal bleeding, ulcerative stomatitis
③ Blood: Agranulocytosis, increased eosinophilia, granulocytopenia, pancytopenia, decreased leukocyte count, decreased platelet count, aplastic anemia, hemolytic anemia, decreased platelet function (prolongation of bleeding time), lymphadenitis.
④ Liver: GOT, increase in GPT level, jaundice, hepatitis, liver failure, cholestasis
⑤ Kidney: Renal disorder, glomerulonephritis, hematuria, nephrotic syndrome, renal papillary necrosis, proteinuria, renal failure, oliguria/polyuria, interstitial renal tubulitis (may progress to renal failure)
⑥ Mental nervous system
- Drowsiness, cognitive dysfunction, rarely dizziness, headache, numbness in the limbs, loss of energy, fatigue, depression, abnormal dreams, loss of concentration, disorientation, insomnia, muscle pain, muscle weakness. Agitation, anxiety, mental confusion, hallucinations, nervousness. lethargy, myasthenia
- Aseptic meningitis (if symptoms such as severe headache, nausea, vomiting, insomnia, stiff neck, fever, or impaired consciousness appear, immediately stop taking the drug and consult a doctor.)
⑦ Respiratory system: Dyspnea, asthma, bronchospasm, eosinophilic pneumonia, pneumonia, pulmonary edema, respiratory depression.
⑧ Skin: itching, ecchymosis, rash, eczema, sweating, purpura, photosensitivity, hair loss, redness, necrolysis, erythema multiforme, Stevens-Johnson syndrome (mucocutaneous ocular syndrome), urticaria, epidermobullosis, erythema nodosum, fixed drug rash, lichen planus, porphyria cutanea tarda, exfoliative dermatitis, pustular reaction.
⑨ Sensory system: tinnitus, hearing impairment, visual impairment
⑩ Metabolism and nutrition: edema, fluid retention, hyperglycemia, hypoglycemia, weight change, hyperkalemia, hyperuricemia
⑪ Infection; Diverticulitis, infection, sepsis
⑫ Others: angioneurotic edema, palpitations, congestive heart failure, stroke, infertility, menstrual disorders, chills, fever, vasculitis, increased serum creatinine level
4) Adverse reactions reported in clinical trials and/or post-marketing surveillance of esomeprazole enteric-coated preparations are as follows. There was no dose correlation.
※ Table: Refer to attached document
*Severe hypomagnesemia may cause hypocalcemia. Hypomagnesemia can also cause hypokalemia.
5) The following are adverse reactions reported through post-marketing surveillance of proton pump inhibitors. Because these adverse reactions are voluntarily reported from an unspecified population, it is not always possible to reliably predict their incidence or establish a causal relationship with drug administration.
- Immune system: Systemic lupus erythematosus
- Skin and subcutaneous tissue system: Cutaneous lupus erythematosus
- Gastrointestinal system: gastric gland polyp
- Metabolism and nutritional system: hypocalcemia, hypokalemia
6) With esomeprazole-containing preparations, rhabdomyolysis may occur, so carefully observe. If symptoms including muscle pain, asthenia, increased creatinine kinase (creatine phosphatase), and elevated blood and urine myoglobin appear, administration should be discontinued and appropriate measures should be taken.
5. General precautions
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. During treatment, the progress should be observed sufficiently and this drug should be administered at the minimum dose and appropriate treatment period depending on the symptoms.
2) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
3) Patients taking this drug for a long period of time (especially over 1 year) should undergo regular examinations. Conduct clinical tests (blood tests such as urinalysis, complete blood count (CBC) and physicochemical tests, liver function tests, ophthalmological tests, etc.), and if any abnormalities are found, take appropriate measures such as reducing the dose or stopping medication. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, treatment with this drug should be discontinued.
4) Observe the patient's condition sufficiently and pay attention to the occurrence of adverse reactions. Excessive temperature drop, collapse, and cooling of extremities may occur, so pay close attention to the patient's condition after administration, especially in the elderly or patients with consumptive diseases. For weak patients, administer with caution in the minimum necessary amount and pay particular attention to the occurrence of adverse reactions.
5) Due to the pharmacological properties of this drug, it may suppress other symptoms and signs of inflammation, delaying the diagnosis of infectious complications under painful and non-infectious conditions.
6) Effects on the gastrointestinal system
① Extreme caution should be exercised when prescribing non-steroidal anti-inflammatory drugs, including naproxen, to patients with a history of ulcerative disease or gastrointestinal bleeding. In patients with a history of peptic ulcer disease and/or gastrointestinal bleeding, the risk of gastrointestinal bleeding increased more than 10 times when taking nonsteroidal anti-inflammatory drugs compared to patients without these risk factors. Other risk factors that increase gastrointestinal bleeding include concurrent use of oral corticosteroids, anticoagulants, long-term use of nonsteroidal anti-inflammatory drugs, alcohol consumption, old age, and poor health. Since most spontaneous reports of fatal gastrointestinal adverse reactions are in elderly and frail patients, special caution should be exercised when administering this drug to these patients. Coadministration with misoprostol or proton pump inhibitors should be considered in these patients.
② If bleeding or ulcers in the gastrointestinal tract occur while taking this medicine, stop taking it.
③ Patients with a history of gastrointestinal diseases (ulcerative colitis, Crohn's disease) should be administered non-steroidal anti-inflammatory drugs with caution as their physical condition may worsen.
④ Someprazole 818.9692.3 may alleviate the symptoms of a malignant tumor or delay the diagnosis, so if there are warning symptoms that suggest a malignant tumor (unintentional significant weight loss, recurrent vomiting, difficulty swallowing, hematemesis or black vomit, etc.) and a gastric ulcer is present or suspected, a test should be performed to confirm the presence of a malignant tumor.
⑤ Administration of proton pump inhibitors may slightly increase the risk of gastrointestinal infections such as Salmonella and Campylobacter.
⑥ Since esomeprazole may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypogastric acidosis or no gastric acidosis, sufficient caution is required in patients with risk factors that reduce vitamin B12 absorption or reduced body storage during long-term treatment.
7) Hypertension: Non-steroidal anti-inflammatory drugs, including this drug, may cause hypertension or worsen existing hypertension, which may increase the incidence of adverse cardiovascular events. Patients taking thiazide diuretics or loop diuretics may have a decreased response to these therapies when taking NSAIDs. Non-steroidal anti-inflammatory drugs, including this drug, should be administered with caution in patients with hypertension. Blood pressure should be closely monitored at the beginning and during treatment of this drug.
8) Congestive heart failure and edema: Fluid retention and edema (including peripheral edema) have been observed in some patients taking non-steroidal anti-inflammatory drugs, including this drug. This drug should be administered with caution to patients with fluid retention or cardiac dysfunction.
9) Long-term use of non-steroidal anti-inflammatory drugs may cause kidney papillary necrosis or other kidney damage. Renal toxicity also occurred in patients in whom renal prostaglandins play a compensatory role in maintaining renal perfusion. In these patients, when NSAIDs are administered, inhibition of prostaglandin production and subsequent decrease in renal blood flow (which can overtly trigger renal failure) may occur in a dose-dependent manner. High-risk groups in which this effect may occur include patients with renal impairment, hypovolemia, heart failure, hepatic impairment, salt depletion patients, patients taking diuretics, ACE inhibitors, or angiotensin II receptor antagonists, and the elderly. When you stop taking non-steroidal anti-inflammatory drugs, most cases return to their pre-treatment state.
10) Advanced renal disease: No controlled clinical trials have been conducted on the use of this drug in patients with advanced renal disease. Therefore, administration of this drug is not recommended for patients with advanced renal disease or patients with creatinine clearance less than 30 mL/min. If treatment with this drug is to be initiated, the patient's renal function should be closely monitored.
11) Administration of non-steroidal anti-inflammatory drugs, including this drug, may result in an increase in liver function levels. These abnormal test values may worsen, remain unchanged, or be temporary as treatment continues. Additionally, serious liver-related adverse reactions, including jaundice, fatal fulminant hepatitis, liver necrosis, and liver failure (some of which were fatal), have been reported rarely with the administration of non-steroidal anti-inflammatory drugs, including this drug.
For patients with symptoms and/or signs suggestive of liver function abnormality or abnormal liver function test results, carefully observe whether liver function deteriorates during the treatment period, and if clinical symptoms or systemic signs related to liver disease (e.g. eosinophilia, rash) appear, administration of this drug should be discontinued.
12) Since anemia may occur due to administration of non-steroidal anti-inflammatory drugs, including this drug, a hemoglobin level or hematocrit test should be performed if symptoms or signs of anemia appear due to long-term administration of this drug.
Non-steroidal anti-inflammatory drugs have been found to inhibit platelet aggregation and prolong bleeding time in some patients. Unlike aspirin, the effects of this drug on platelet function are relatively small, short-lived, and reversible. Patients who may be adversely affected by altered platelet function, such as those with coagulation-related disorders or those taking anticoagulants, should be carefully monitored when receiving this drug.
13) Anaphylactoid reaction: Like other non-steroidal anti-inflammatory drugs, anaphylactoid reaction can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who present with severe, potentially fatal bronchospasm with or without nasal polyps following administration of aspirin or other NSAIDs. If such an anaphylactoid reaction occurs, emergency treatment must be administered.
14) Skin reactions: This drug may cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, acute generalized pyknotic pustulosis, eosinophilia, and drug reaction with systemic symptoms (DRESS syndrome), which may be fatal. These serious adverse reactions may occur without warning symptoms. In most cases, these adverse reactions occur within the first month of administration. Increased eosinophils and drug reactions with systemic symptoms (DRESS syndrome) have been reported in patients taking nonsteroidal anti-inflammatory drugs. Patients should be aware of serious skin signs and symptoms and should discontinue medication at the first sign or sign of skin rash or other hypersensitivity reaction.
15) Eye-related: If visual disturbances or other changes occur, an ophthalmic examination is recommended.
16) Some asthma patients may react sensitively to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. Cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in these aspirin-sensitive patients. Therefore, this drug should not be administered to aspirin-sensitive patients and should be used with caution in asthma patients.
17) This drug cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroids may result in worsening of corticosteroid-responsive disease. If this drug is to be administered to a patient who has been taking corticosteroids for a long period of time, the dose should be gradually reduced.
18) Non-steroidal anti-inflammatory drugs, including naproxen, may cause female reproductive disorders (infertility), so they are not recommended for women trying to become pregnant. Discontinuation of medication should be considered for women who are having difficulty conceiving or are undergoing infertility testing.
19) Some overseas epidemiological studies have reported that proton pump inhibitor treatment may be associated with an increased risk of hip, wrist, and spine fractures. The risk of fracture was increased in patients receiving higher doses than the recommended dose and in patients using the drug for long-term use of more than 1 year. Although the causal relationship between omeprazole and esomeprazole and osteoporotic fractures has not been determined, appropriate clinical monitoring is recommended according to the latest clinical guidelines for patients at risk of developing osteoporosis and osteoporotic fractures.
20) This drug may cause drowsiness, asthenia, and fatigue, which may reduce reaction ability, so be careful when driving or operating machinery.
21) Hypomagnesemia was rarely reported in patients treated with proton pump inhibitors for more than 3 months, and was most common in patients treated for more than 1 year. For most patients, magnesium supplementation and discontinuation of proton pump inhibitor administration are necessary to treat hypomagnesemia. Patients requiring long-term treatment or taking concomitant medications such as digoxin or drugs that cause hypomagnesemia (e.g. diuretics) require periodic monitoring of magnesium levels, including at the start of treatment. Serious adverse reactions include rigidity, arrhythmias, and seizures.
22) Methotrexate: There have been literature reports that when proton pump inhibitors and methotrexate are used together (mainly when using high doses, see “Precautions for Use” of methotrexate), the serum concentration of methotrexate and/or its metabolites increases and persists, leading to methotrexate toxicity. When using high doses of methotrexate, temporary discontinuation of proton pump inhibitor administration may be considered (see 「6. Interactions」).
23) Skin and systemic lupus erythematosus: Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking proton pump inhibitors. These cases occurred newly or due to worsening of existing autoimmune diseases. Most cases of lupus erythematosus caused by proton pump inhibitors were cutaneous lupus erythematosus.
The most common form of cutaneous lupus erythematosus reported in patients taking proton pump inhibitors is subacute cutaneous lupus erythematosus, which occurs within weeks to years of continuous drug treatment in patients ranging from infants to the elderly. In general, histological results showed no organ invasion.
Systemic lupus erythematosus has been reported less commonly than cutaneous lupus erythematosus in patients taking proton pump inhibitors. Proton pump inhibitor-related systemic lupus erythematosus usually shows milder symptoms than non-drug-induced systemic lupus erythematosus. Systemic lupus erythematosus mainly occurs within a few days to several years after initial drug treatment in young adults to the elderly. The majority of patients presented with a rash, but arthralgia and cytopenias were also reported.
Do not take proton pump inhibitors for longer than medically indicated. If a patient taking this drug develops symptoms or signs consistent with cutaneous lupus erythematosus or systemic lupus erythematosus, stop taking the drug and refer the patient to an appropriate specialist for evaluation. Most patients improved simply by discontinuing proton pump inhibitors within 4 to 12 weeks. Serological tests (e.g., antinuclear antibody (ANA)) may be positive, and high serological test results may take longer to resolve than clinical symptoms.
24) Fundic gland polyps: The use of proton pump inhibitors is associated with an increased risk of fundic gland polyps, especially when used for a year or more. Among patients using proton pump inhibitors, most patients who developed gastric fundic polyps were asymptomatic and discovered accidentally through endoscopy. Proton pump inhibitors should be used for the shortest period of time according to the symptoms being treated.
25) Acute interstitial renal tubulitis: Acute interstitial renal tubulitis has been observed in patients receiving medications containing esomeprazole and naproxen, and may occur at any time during treatment with this drug. Acute interstitial renal tubulitis may progress to renal failure. Patients suspected of having acute interstitial renal tubulitis should discontinue treatment with this drug and promptly take appropriate measures.
6. Drug interactions
1) Antiretroviral drugs:
① Atazanavir: When omeprazole (20 mg administered once daily) and atazanavir 300 mg/ritonavir 100 mg were coadministered to healthy volunteers, the exposure to atazanavir decreased (AUC, Cmax, and Cmin decreased by approximately 75%). Administration of atazanavir 400 mg four times daily cannot offset the effect of omeprazole on atanazavir exposure. Therefore, it should not be administered together with this drug.
② Nelfinavir: When co-administered with omeprazole (40 mg per day), the average AUC, Cmax, and Cmin of nelfinavir decreased by 36 to 39%. The average AUC, Cmax, and Cmin of the active metabolite M8 (hydroxy-t-butylamide) decreased by 75-92%. Therefore, it should not be administered together with this drug.
③ Saquinavir: When co-administered with omeprazole (40 mg per day), the blood concentration of saquinavir may increase and the risk of adverse reactions may increase. Therefore, administer with caution, such as reducing the dose according to the patient's individual condition.
2) Other non-steroidal anti-inflammatory drugs (NSAIDs), including COX-2 selective inhibitors: Do not use together with naproxen derivatives because the risk of adverse reactions such as gastrointestinal ulcers and bleeding may increase.
3) Hydantoin antiepileptic drugs, sulfa drugs, and sulfonylurea hypoglycemic agents: When administered together with these drugs, their action may be enhanced, so observe carefully and administer carefully.
4) Propranolol and other β-blockers: Co-administration with this drug may reduce the antihypertensive effect.
5) ACE inhibitors (captopril, etc.)/Angiotensin II receptor antagonists
There are reports that non-steroidal anti-inflammatory drugs may attenuate the antihypertensive effects of ACE inhibitors and angiotensin II receptor antagonists. NSAIDs may also increase the risk of renal impairment associated with the use of ACE inhibitors or angiotensin II receptor antagonists. Caution is required when coadministering nonsteroidal anti-inflammatory drugs and ACE inhibitors or angiotensin II receptor antagonists in the elderly, patients with hypovolemia, or renal impairment.
6) Loop diuretics and thiazide diuretics
① As a result of clinical trials and post-marketing surveillance, it was confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some patients due to this drug's inhibition of prostaglandin synthesis in the kidneys. Patients should be closely monitored for signs of renal failure during concurrent use of these drugs and nonsteroidal anti-inflammatory drugs.
② This drug may reduce the action of loop diuretics (furosemide, piretanide) and thiazide diuretics, so administer with caution when administered together.
7) Probenecid: When co-administered, the blood concentration of this drug increases and the half-life in the blood is prolonged, so administer with caution, including reducing the dose.
8) Aspirin: There is no consistent evidence that combined use with aspirin can reduce the risk of serious cardiovascular thrombotic events associated with the use of nonsteroidal anti-inflammatory drugs. As with other non-steroidal anti-inflammatory drugs, the combined use of this drug and aspirin may increase the risk of serious gastrointestinal adverse reactions, so the combined use of the two drugs is generally not recommended.
Clinical pharmacodynamic information suggests that coadministration of aspirin and naproxen for more than two consecutive days may inhibit the effects of low-dose aspirin on platelet activity, which may persist for up to several days after naproxen treatment is discontinued. The clinical relevance of this interaction is unknown.
9) Lithium: Non-steroidal anti-inflammatory drugs can increase serum lithium concentration and reduce renal clearance of lithium by inhibiting prostaglandin synthesis in the kidney. Co-administration of non-steroidal anti-inflammatory analgesics and lithium may cause lithium poisoning, so when used together, lithium must be administered with caution, including carefully observing signs of toxicity and reducing the dosage.
10) Methotrexate
Increased methotrexate levels have been reported in some patients when administered with proton pump inhibitors. Co-administration with non-steroidal anti-inflammatory drugs (NSAIDs) delays the excretion of methotrexate from the renal tubules, which may increase the fatal hematological toxicity of methotrexate. Therefore, it should not be administered in combination with high-dose methotrexate used in anticancer therapy, and must be administered with caution when administered in combination with low-dose methotrexate.
11) Coumarin-based anticoagulants (warfarin, etc.)
(1) For gastrointestinal bleeding, warfarin and non-steroidal anti-inflammatory drugs may have a synergistic effect, so patients who use both drugs together may have an increased risk of severe gastrointestinal bleeding compared to those who take the two drugs alone.
(2) When coadministered with coumarin-based anticoagulants, its action may be enhanced, so observe carefully and administer carefully.
12) Zidovudine: It may inhibit the metabolism of zidovudine and increase its blood concentration, so when used together, administer with caution, such as reducing the dose.
13) New quinolone antibiotics (enoxacin, etc.): Administer with caution as concurrent use with this drug may cause convulsions.
14) Cyclosporine and tacrolimus: When administered together with esomeprazole, the blood concentration of tacrolimus may increase. There is a risk of nephrotoxicity when NSAIDs and cyclosporine or tacrolimus are coadministered.
15) Selective serotonin reuptake inhibitors (SSRIs): Co-administration of NSAIDs, including COX-2 selective inhibitors, and SSRIs increases the risk of gastrointestinal bleeding.
16) Corticosteroids: When NSAIDs, including COX-2 selective inhibitors, are administered together with corticosteroids, the risk of gastrointestinal bleeding increases.
17) Cholestyramine: Absorption may be delayed when administered in combination with non-steroidal anti-inflammatory painkillers, including naproxen.
18) When administered in combination with cardiac glycosides such as digoxin, NSAIDs may increase the plasma concentration of cardiac glycosides. Additionally, when digoxin and omeprazole (20 mg per day) were co-administered in healthy patients, the bioavailability of digoxin increased by up to 10% (from 2 out of 10 to 30%).
19) Clopidogrel: From the results of studies in healthy volunteers, clopidogrel (initial dose 300 mg/maintenance dose 75 mg daily) and esomeprazole (orally administered 40 mg daily) appear to have a pharmacokinetic/pharmacodynamic interaction, which appears to reduce platelet aggregation by an average of 14% and reduces exposure to the active metabolite of clopidogrel by an average of 40%. appeared. Based on these results, esomeprazole and clopidogrel should not be administered together.
20) Drugs whose absorption is affected by gastric acidity: The absorption of drugs whose absorption mechanism is affected by gastric acidity may increase or decrease due to the decrease in gastric acidity during administration of this drug. As with other acid secretion suppressants and antacids, the absorption of ketoconazole and itraconazole may be reduced during administration of this drug.
21) CYP2C19, CYP3A4 inhibitors/inducers and substrates
Esomeprazole is metabolized by CYP2C19 and CYP3A4. It also inhibits CYP2C19, the main metabolic enzyme.
(1) When used together with drugs metabolized by CYP2C19, such as diazepam, citalopram, imipramine, clomipramine, phenytoin, warfarin, etc., the plasma concentration of these drugs may increase, so a dose reduction of these drugs may be necessary. Co-administration of 30 mg of diazepam, a CYP2C19 substrate, and esomeprazole reduced the clearance of diazepam by 45%.
(2) Co-administration of phenytoin and esomeprazole 40 mg to epilepsy patients increased the minimum plasma concentration of phenytoin by 13%. Monitor phenytoin plasma concentrations when starting or discontinuing treatment with this drug.
(3) Omeprazole (40 mg administered once daily) increased the Cmax and AUCτ of voriconazole (CYP2C19 substrate) by 15% and 41%, respectively.
(4) When esomeprazole and clarithromycin (500 mg administered twice daily), a CYP3A4 inhibitor, are administered simultaneously, the AUC of esomeprazole is doubled.
(5) Drugs known to be CYP2C19 and/or CYP3A4 inducers (e.g., rifampicin, St. John's wort) may decrease esomeprazole blood concentrations by increasing esomeprazole metabolism.
22) Cilostazol: In a crossover study in which 40 mg of omeprazole was administered to healthy patients, cilostazol Cmax and AUC increased by 18% and 26%, respectively. Among the active metabolites, 3,4-dihydrocilostazol increased Cmax and AUC by 29% and 69%, respectively.
23) Rilpivirine: When this drug and rilpivirine are used together, the plasma concentration of rilpivirine may decrease (increased gastric pH), so co-administration should not be performed. This may reduce the therapeutic effect of rilpivirine.
7. Administration to pregnant and lactating women
1) Fertility: Non-steroidal anti-inflammatory drugs such as naproxen can impair female fertility. Animal experiments have shown that non-steroidal anti-inflammatory drugs such as naproxen can suppress ovulation. Women who have difficulty conceiving or who are being investigated for infertility should consider discontinuing treatment with nonsteroidal anti-inflammatory drugs, including this drug.
2) Pregnant women: There are no well-controlled clinical data on the administration of this drug to pregnant women. Regarding naproxen, this drug should not be administered in the last trimester of pregnancy.
① Naproxen: In animal tests, naproxen did not show any direct or indirect harm related to embryo-fetal development. Epidemiological data from human studies have shown that the use of non-steroidal anti-inflammatory drugs during early pregnancy may increase the risk of miscarriage. Congenital malformations associated with NSAID administration have been reported in humans, but the frequency was low and there was no clear trend. As with other drugs of the same type, naproxen has been reported to cause delayed labor, increased incidence of dystocia, and reduced survival rate of offspring in animal experiments (pre- and postnatal period). When administered at the end of pregnancy, contraction of the ductus arteriosus in the fetus was observed. It also affected the cardiovascular system, including premature occlusion of the ductus arteriosus in the human fetus. Therefore, naproxen should not be administered during the third trimester of pregnancy. Use of non-steroidal anti-inflammatory drugs after 20 weeks of pregnancy can cause abnormalities in renal function in the fetus, resulting in oligohydramnios and, in some cases, neonatal renal failure. Ultrasound monitoring of amniotic fluid volume is considered in pregnant women who require administration of this drug. Nonsteroidal anti-inflammatory drugs should be administered to women planning to become pregnant or in the first or second trimester of pregnancy only when the potential benefit to the patient outweighs the potential risk to the fetus. When using this drug, it should be administered at the lowest dose and shortest treatment period. It is not recommended to use naproxen-containing preparations during labor or delivery because naproxen may adversely affect fetal circulation through its action of inhibiting prostaglandin synthesis and may inhibit contractions by increasing the bleeding tendency for both mother and fetus.
② Esomeprazole: Clinical data on the administration of esomeprazole to pregnant women is limited. Animal testing of esomeprazole did not show direct or indirect harmful effects on embryo-fetal development. Animal tests on the racemic mixture did not show direct or indirect harmful effects on pregnancy, parturition, or postnatal development. Nevertheless, caution should be exercised when administering this drug to pregnant women.
3) Nursing mothers: Naproxen in this drug is transferred to breast milk and causes adverse reactions that inhibit prostaglandin synthesis in newborns, so it should not be administered to nursing mothers.
8. Administration to children
Administration is not recommended for children under 18 years of age because safety and effectiveness have not been established.
9. Administration to elderly people
In general, elderly people are more prone to gastrointestinal ulcers and bleeding caused by anti-inflammatory painkillers, so they should be administered in the minimum necessary amount and administered carefully while observing the patient's condition, paying particular attention to the occurrence of adverse reactions, or consider administering other alternative medications.
10. Effect on clinical test values
1) Be careful when measuring bleeding time as it may inhibit platelet aggregation and prolong bleeding time.
2) Because it affects the measurement of 17-ketogenic steroids, discontinue administration of this drug 72 hours before measurement.
3) Naproxen may affect urine analysis of 5-hydroxy indole acetic acid (5HIAA).
4) The decrease in gastric acidity caused by the administration of this drug increases the concentration of serum chromogranin A (CgA). Therefore, people taking this drug may experience false positive results in neuroendocrine tumor diagnostic tests. Administration of this drug should be temporarily discontinued at least 14 days before the CgA test. If the test value exceeds the upper reference limit, retesting should be considered. When tests are performed repeatedly (e.g., monitoring), concentration measurements should be performed in the same laboratory because reference ranges differ between laboratories.
11. Treatment in case of overdose
There is no clinical trial data on overdose of this drug. The effects of overdose of this drug are expected to primarily reflect the effects of overdose of naproxen.
1) Symptoms
① Overdosage of naproxen may cause lethargy, dizziness, drowsiness, epigastric pain, abdominal discomfort, heartburn, indigestion, nausea, temporary worsening of liver function, hypoprothrombinemia, abnormal renal function, metabolic acidosis, apnea, disorientation, vomiting, gastrointestinal bleeding, hypertension, acute renal failure, respiratory depression, coma, and anaphylactoid reaction. You can.
② Symptoms associated with planned esomeprazole overdose (limited experience exceeding 240 mg of esomeprazole per day) were temporary. When taking 280 mg of this drug, gastrointestinal symptoms and weakness appeared. There were no significant problems when 80 mg of this drug was administered once.
2) Measures in case of overdose
There is no known specific antidote for naproxen and esomeprazole. Neither component is dialyzed. Therefore, symptomatic treatment and general maintenance treatment, such as gastric lavage and medicinal charcoal to reduce plasma concentration, should be used.
12. Precautions for application
1) This medicine consists of an immediate-release layer of esomeprazole, which dissolves in the stomach, and an enteric layer of naproxen, which dissolves in the small intestine. When administering, do not split, chew, or crush, but swallow it as is with water.
2) When taking this medicine after a meal, the absorption rate of esomeprazole in the body is reduced, so take it 30 minutes before a meal.
13. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
14. Pharmaceutical equivalence test information
A. Esomeprazole
The test drug Nasopra Tablet 500/20 mg [KyungDong Pharm Co., Ltd.] and the reference drug Vimobojeong 500/20 mg [LG Chemical Co., Ltd.] were administered orally once on an empty stomach to 47 healthy adults in a 2×4 cross-over test to measure esomeprazole in the blood. When the comparative evaluation item values (AUCt, Cmax) were log-transformed and subjected to statistical processing, the difference in average values was found to be The 90% confidence interval was within the equivalence standard, demonstrating biological equivalence.
※ Table: Refer to attached document
B. Naproxen
The test drug Nasopra Tablet 500/20 mg [KyungDong Pharm Co., Ltd.] and the reference drug Bimobojeong 500/20 mg [LG Chemical Co., Ltd.] were orally administered to healthy adults as a single tablet each on an empty stomach and after a meal in a 2×2 cross-over study. Naproxen in the blood of 50 people (fasting) and 53 people (after a meal) was measured, and comparative evaluation items (AUCt, Cmax) were obtained. When log transformed and subjected to statistical processing, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.
<empty stomach>
※ Table: Refer to attached document
<After meal>
※ Table: Refer to attached document
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Period of use
24 months from date of manufacture
- Active ingredient: Naproxen (USP) · · · · · · · 500mg
Esomeprazole Magnesium Trihydrate (USP) · · · · · · · 22.3mg (20mg as Esomeprazole)
- Additives: 30% dispersion of methacrylic acid/ethyl acrylate copolymer (1:1), titanium oxide, magnesium stearate, opadry yellow (03B62519), precipitated calcium carbonate, carnauba lead, colloidal silicon oxide, croscarmellose sodium, triethyl citrate, povidone, Polysorbate 80, polyethylene glycol 6000, plastic acrylic tea 20, hypromellose
2. Effectiveness
Treatment of symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients who are at risk of developing gastric and/or duodenal ulcers related to non-steroidal anti-inflammatory drugs (naproxen, etc.) and who are not adequately treated with low-dose naproxen or other non-steroidal anti-inflammatory drugs.
3. Dosage and dosage
Adults: Administer orally twice a day, 1 tablet each time (naproxen 500mg/esomeprazole 20mg).
Do not split, chew, or crush this medicine; swallow it as is with water. It is recommended to take it at least 30 minutes before a meal.
4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.
2) Cardiovascular risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious cardiovascular thrombotic reactions, myocardial infarction and stroke, which can be fatal. This risk may occur as early as the first week of treatment and may increase with duration of treatment. An increased risk of cardiovascular thrombosis was consistently observed at higher doses. Patients with cardiovascular disease (e.g., uncontrolled hypertension, congestive heart failure, ischemic heart disease, peripheral artery disease, and/or cerebrovascular disease) and patients with risk factors for cardiovascular disease (e.g., hypertension, hyperlipidemia, diabetes, and smoking) may be at greater risk and should be treated with this drug after careful consideration. Physicians and patients must carefully monitor the development of these cardiovascular symptoms, even if there is no history of cardiovascular disease. Patients should be informed in advance about signs and/or symptoms of serious cardiovascular toxicity and what measures to take if these symptoms occur.
3) Gastrointestinal risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious gastrointestinal adverse reactions, including gastric or intestinal bleeding, ulceration, and perforation, which may be fatal. Compared to naproxen administered alone, this drug significantly reduced the occurrence of gastric ulcers, but ulcers and related complications still occur. These adverse reactions may occur without warning symptoms during the administration period. Older adults may be at greater risk for serious gastrointestinal adverse events.
The longer the administration period, the more likely it is that serious gastrointestinal side effects will occur, but this risk cannot be completely ruled out during short-term administration.
While administering this drug, patients should be carefully monitored for symptoms and signs of gastrointestinal ulcers or bleeding, and if serious adverse gastrointestinal reactions are suspected, additional evaluation and treatment should be performed immediately. Discontinuing the administration of non-steroidal anti-inflammatory drugs until severe gastrointestinal side effects are completely ruled out can also be a treatment option. For patients at high risk, alternative treatments unrelated to NSAIDs should be considered.
2. Do not administer to the following patients.
1) Patients with hypersensitivity to naproxen, esomeprazole, substituent benzimidazole, and other components of this drug
2) Patients with asthma, rhinitis, nasal polyps, urticaria, allergic reactions or a history of such reactions due to administration of aspirin or other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors) (In these patients, severe and fatal anaphylactoid reactions have been rarely reported after administration of non-steroidal anti-inflammatory drugs).
3) Patients with active peptic ulcer
4) Patients with gastrointestinal bleeding, cerebrovascular hemorrhage, other bleeding diseases, and patients with severe blood abnormalities
5) Patients with severe hepatic impairment (e.g. Childs-Pugh class C)
6) Patients with severe heart failure
7) Patients with severe renal impairment (creatinine clearance less than 30mL/min)
8) Patients with severe high blood pressure
9) Treatment of pain occurring before and after coronary artery bypass surgery (CABG)
10) Pregnant women in the last 3 months of pregnancy
11) Patients receiving atazanavir, nelfinavir
12) Patients taking rilpivirine-containing preparations (see 「6. Interactions」)
3. Administer with caution to the following patients.
1) Patients with a history of peptic ulcer
2) Patients with blood abnormalities or their history
3) Patients with bleeding tendencies (platelet function decline may occur.)
4) Patients with hepatic impairment or its history
5) Patients with renal impairment or its history and patients with reduced renal blood flow
6) Patients with cardiac dysfunction
7) Patients with high blood pressure
8) Patients with a history of hypersensitivity
9) Patients with bronchial asthma
10) Patients with induced porphyria, patients with systemic lupus erythematosus (SLE), and patients with mixed connective tissue disease (MCTD)
11) Elderly people
4. Adverse reactions
1) As a result of comparing the safety data of the group administered this drug (n=1157) and the main ingredients of this drug, naproxen and esomeprazole, there was no newly added safety information.
2) In clinical trials, adverse reactions that occurred when administering this drug were classified according to frequency and organ of occurrence (SOC; System Organ Class) as follows. Frequency is defined as follows: Very common (>1/10), common (>1/100, <1/10), uncommon (>1/1,000, <1/100), rare (>1/10,000, <1/1,000), very rare (<1/10,000), unknown (not measured in available data)
※ Table: Refer to attached document
*Confirmed by planned routine endoscopy.
3) Adverse reactions in clinical trials and post-marketing surveillance of naproxen are as follows.
① Hypersensitivity: Shock symptoms (difficulty breathing, lowered blood pressure, bradycardia, cold sweat, edema, etc.), PIE syndrome (pulmonary infiltration accompanied by eosinophilia: accompanied by fever, wheezing, cough, and phlegm), anaphylactoid reaction, hives, rash, itching, etc.
② Digestive system: Hematemesis, gastrointestinal bleeding, peptic ulcer, perforation, stomach discomfort, stomach pain, abdominal pain, nausea, vomiting, loss of appetite, indigestion, heartburn, diarrhea, constipation, stomatitis, abdominal bloating, black stool, dry mouth, esophagitis, gastritis, glossitis, eructation, flatulence, melanosis, pancreatitis, colitis, worsening of inflammatory bowel disease (ulcerative colitis, Crohn's disease), Rectal bleeding, ulcerative stomatitis
③ Blood: Agranulocytosis, increased eosinophilia, granulocytopenia, pancytopenia, decreased leukocyte count, decreased platelet count, aplastic anemia, hemolytic anemia, decreased platelet function (prolongation of bleeding time), lymphadenitis.
④ Liver: GOT, increase in GPT level, jaundice, hepatitis, liver failure, cholestasis
⑤ Kidney: Renal disorder, glomerulonephritis, hematuria, nephrotic syndrome, renal papillary necrosis, proteinuria, renal failure, oliguria/polyuria, interstitial renal tubulitis (may progress to renal failure)
⑥ Mental nervous system
- Drowsiness, cognitive dysfunction, rarely dizziness, headache, numbness in the limbs, loss of energy, fatigue, depression, abnormal dreams, loss of concentration, disorientation, insomnia, muscle pain, muscle weakness. Agitation, anxiety, mental confusion, hallucinations, nervousness. lethargy, myasthenia
- Aseptic meningitis (if symptoms such as severe headache, nausea, vomiting, insomnia, stiff neck, fever, or impaired consciousness appear, immediately stop taking the drug and consult a doctor.)
⑦ Respiratory system: Dyspnea, asthma, bronchospasm, eosinophilic pneumonia, pneumonia, pulmonary edema, respiratory depression.
⑧ Skin: itching, ecchymosis, rash, eczema, sweating, purpura, photosensitivity, hair loss, redness, necrolysis, erythema multiforme, Stevens-Johnson syndrome (mucocutaneous ocular syndrome), urticaria, epidermobullosis, erythema nodosum, fixed drug rash, lichen planus, porphyria cutanea tarda, exfoliative dermatitis, pustular reaction.
⑨ Sensory system: tinnitus, hearing impairment, visual impairment
⑩ Metabolism and nutrition: edema, fluid retention, hyperglycemia, hypoglycemia, weight change, hyperkalemia, hyperuricemia
⑪ Infection; Diverticulitis, infection, sepsis
⑫ Others: angioneurotic edema, palpitations, congestive heart failure, stroke, infertility, menstrual disorders, chills, fever, vasculitis, increased serum creatinine level
4) Adverse reactions reported in clinical trials and/or post-marketing surveillance of esomeprazole enteric-coated preparations are as follows. There was no dose correlation.
※ Table: Refer to attached document
*Severe hypomagnesemia may cause hypocalcemia. Hypomagnesemia can also cause hypokalemia.
5) The following are adverse reactions reported through post-marketing surveillance of proton pump inhibitors. Because these adverse reactions are voluntarily reported from an unspecified population, it is not always possible to reliably predict their incidence or establish a causal relationship with drug administration.
- Immune system: Systemic lupus erythematosus
- Skin and subcutaneous tissue system: Cutaneous lupus erythematosus
- Gastrointestinal system: gastric gland polyp
- Metabolism and nutritional system: hypocalcemia, hypokalemia
6) With esomeprazole-containing preparations, rhabdomyolysis may occur, so carefully observe. If symptoms including muscle pain, asthenia, increased creatinine kinase (creatine phosphatase), and elevated blood and urine myoglobin appear, administration should be discontinued and appropriate measures should be taken.
5. General precautions
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. During treatment, the progress should be observed sufficiently and this drug should be administered at the minimum dose and appropriate treatment period depending on the symptoms.
2) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
3) Patients taking this drug for a long period of time (especially over 1 year) should undergo regular examinations. Conduct clinical tests (blood tests such as urinalysis, complete blood count (CBC) and physicochemical tests, liver function tests, ophthalmological tests, etc.), and if any abnormalities are found, take appropriate measures such as reducing the dose or stopping medication. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, treatment with this drug should be discontinued.
4) Observe the patient's condition sufficiently and pay attention to the occurrence of adverse reactions. Excessive temperature drop, collapse, and cooling of extremities may occur, so pay close attention to the patient's condition after administration, especially in the elderly or patients with consumptive diseases. For weak patients, administer with caution in the minimum necessary amount and pay particular attention to the occurrence of adverse reactions.
5) Due to the pharmacological properties of this drug, it may suppress other symptoms and signs of inflammation, delaying the diagnosis of infectious complications under painful and non-infectious conditions.
6) Effects on the gastrointestinal system
① Extreme caution should be exercised when prescribing non-steroidal anti-inflammatory drugs, including naproxen, to patients with a history of ulcerative disease or gastrointestinal bleeding. In patients with a history of peptic ulcer disease and/or gastrointestinal bleeding, the risk of gastrointestinal bleeding increased more than 10 times when taking nonsteroidal anti-inflammatory drugs compared to patients without these risk factors. Other risk factors that increase gastrointestinal bleeding include concurrent use of oral corticosteroids, anticoagulants, long-term use of nonsteroidal anti-inflammatory drugs, alcohol consumption, old age, and poor health. Since most spontaneous reports of fatal gastrointestinal adverse reactions are in elderly and frail patients, special caution should be exercised when administering this drug to these patients. Coadministration with misoprostol or proton pump inhibitors should be considered in these patients.
② If bleeding or ulcers in the gastrointestinal tract occur while taking this medicine, stop taking it.
③ Patients with a history of gastrointestinal diseases (ulcerative colitis, Crohn's disease) should be administered non-steroidal anti-inflammatory drugs with caution as their physical condition may worsen.
④ Someprazole 818.9692.3 may alleviate the symptoms of a malignant tumor or delay the diagnosis, so if there are warning symptoms that suggest a malignant tumor (unintentional significant weight loss, recurrent vomiting, difficulty swallowing, hematemesis or black vomit, etc.) and a gastric ulcer is present or suspected, a test should be performed to confirm the presence of a malignant tumor.
⑤ Administration of proton pump inhibitors may slightly increase the risk of gastrointestinal infections such as Salmonella and Campylobacter.
⑥ Since esomeprazole may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypogastric acidosis or no gastric acidosis, sufficient caution is required in patients with risk factors that reduce vitamin B12 absorption or reduced body storage during long-term treatment.
7) Hypertension: Non-steroidal anti-inflammatory drugs, including this drug, may cause hypertension or worsen existing hypertension, which may increase the incidence of adverse cardiovascular events. Patients taking thiazide diuretics or loop diuretics may have a decreased response to these therapies when taking NSAIDs. Non-steroidal anti-inflammatory drugs, including this drug, should be administered with caution in patients with hypertension. Blood pressure should be closely monitored at the beginning and during treatment of this drug.
8) Congestive heart failure and edema: Fluid retention and edema (including peripheral edema) have been observed in some patients taking non-steroidal anti-inflammatory drugs, including this drug. This drug should be administered with caution to patients with fluid retention or cardiac dysfunction.
9) Long-term use of non-steroidal anti-inflammatory drugs may cause kidney papillary necrosis or other kidney damage. Renal toxicity also occurred in patients in whom renal prostaglandins play a compensatory role in maintaining renal perfusion. In these patients, when NSAIDs are administered, inhibition of prostaglandin production and subsequent decrease in renal blood flow (which can overtly trigger renal failure) may occur in a dose-dependent manner. High-risk groups in which this effect may occur include patients with renal impairment, hypovolemia, heart failure, hepatic impairment, salt depletion patients, patients taking diuretics, ACE inhibitors, or angiotensin II receptor antagonists, and the elderly. When you stop taking non-steroidal anti-inflammatory drugs, most cases return to their pre-treatment state.
10) Advanced renal disease: No controlled clinical trials have been conducted on the use of this drug in patients with advanced renal disease. Therefore, administration of this drug is not recommended for patients with advanced renal disease or patients with creatinine clearance less than 30 mL/min. If treatment with this drug is to be initiated, the patient's renal function should be closely monitored.
11) Administration of non-steroidal anti-inflammatory drugs, including this drug, may result in an increase in liver function levels. These abnormal test values may worsen, remain unchanged, or be temporary as treatment continues. Additionally, serious liver-related adverse reactions, including jaundice, fatal fulminant hepatitis, liver necrosis, and liver failure (some of which were fatal), have been reported rarely with the administration of non-steroidal anti-inflammatory drugs, including this drug.
For patients with symptoms and/or signs suggestive of liver function abnormality or abnormal liver function test results, carefully observe whether liver function deteriorates during the treatment period, and if clinical symptoms or systemic signs related to liver disease (e.g. eosinophilia, rash) appear, administration of this drug should be discontinued.
12) Since anemia may occur due to administration of non-steroidal anti-inflammatory drugs, including this drug, a hemoglobin level or hematocrit test should be performed if symptoms or signs of anemia appear due to long-term administration of this drug.
Non-steroidal anti-inflammatory drugs have been found to inhibit platelet aggregation and prolong bleeding time in some patients. Unlike aspirin, the effects of this drug on platelet function are relatively small, short-lived, and reversible. Patients who may be adversely affected by altered platelet function, such as those with coagulation-related disorders or those taking anticoagulants, should be carefully monitored when receiving this drug.
13) Anaphylactoid reaction: Like other non-steroidal anti-inflammatory drugs, anaphylactoid reaction can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who present with severe, potentially fatal bronchospasm with or without nasal polyps following administration of aspirin or other NSAIDs. If such an anaphylactoid reaction occurs, emergency treatment must be administered.
14) Skin reactions: This drug may cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, acute generalized pyknotic pustulosis, eosinophilia, and drug reaction with systemic symptoms (DRESS syndrome), which may be fatal. These serious adverse reactions may occur without warning symptoms. In most cases, these adverse reactions occur within the first month of administration. Increased eosinophils and drug reactions with systemic symptoms (DRESS syndrome) have been reported in patients taking nonsteroidal anti-inflammatory drugs. Patients should be aware of serious skin signs and symptoms and should discontinue medication at the first sign or sign of skin rash or other hypersensitivity reaction.
15) Eye-related: If visual disturbances or other changes occur, an ophthalmic examination is recommended.
16) Some asthma patients may react sensitively to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. Cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in these aspirin-sensitive patients. Therefore, this drug should not be administered to aspirin-sensitive patients and should be used with caution in asthma patients.
17) This drug cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroids may result in worsening of corticosteroid-responsive disease. If this drug is to be administered to a patient who has been taking corticosteroids for a long period of time, the dose should be gradually reduced.
18) Non-steroidal anti-inflammatory drugs, including naproxen, may cause female reproductive disorders (infertility), so they are not recommended for women trying to become pregnant. Discontinuation of medication should be considered for women who are having difficulty conceiving or are undergoing infertility testing.
19) Some overseas epidemiological studies have reported that proton pump inhibitor treatment may be associated with an increased risk of hip, wrist, and spine fractures. The risk of fracture was increased in patients receiving higher doses than the recommended dose and in patients using the drug for long-term use of more than 1 year. Although the causal relationship between omeprazole and esomeprazole and osteoporotic fractures has not been determined, appropriate clinical monitoring is recommended according to the latest clinical guidelines for patients at risk of developing osteoporosis and osteoporotic fractures.
20) This drug may cause drowsiness, asthenia, and fatigue, which may reduce reaction ability, so be careful when driving or operating machinery.
21) Hypomagnesemia was rarely reported in patients treated with proton pump inhibitors for more than 3 months, and was most common in patients treated for more than 1 year. For most patients, magnesium supplementation and discontinuation of proton pump inhibitor administration are necessary to treat hypomagnesemia. Patients requiring long-term treatment or taking concomitant medications such as digoxin or drugs that cause hypomagnesemia (e.g. diuretics) require periodic monitoring of magnesium levels, including at the start of treatment. Serious adverse reactions include rigidity, arrhythmias, and seizures.
22) Methotrexate: There have been literature reports that when proton pump inhibitors and methotrexate are used together (mainly when using high doses, see “Precautions for Use” of methotrexate), the serum concentration of methotrexate and/or its metabolites increases and persists, leading to methotrexate toxicity. When using high doses of methotrexate, temporary discontinuation of proton pump inhibitor administration may be considered (see 「6. Interactions」).
23) Skin and systemic lupus erythematosus: Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking proton pump inhibitors. These cases occurred newly or due to worsening of existing autoimmune diseases. Most cases of lupus erythematosus caused by proton pump inhibitors were cutaneous lupus erythematosus.
The most common form of cutaneous lupus erythematosus reported in patients taking proton pump inhibitors is subacute cutaneous lupus erythematosus, which occurs within weeks to years of continuous drug treatment in patients ranging from infants to the elderly. In general, histological results showed no organ invasion.
Systemic lupus erythematosus has been reported less commonly than cutaneous lupus erythematosus in patients taking proton pump inhibitors. Proton pump inhibitor-related systemic lupus erythematosus usually shows milder symptoms than non-drug-induced systemic lupus erythematosus. Systemic lupus erythematosus mainly occurs within a few days to several years after initial drug treatment in young adults to the elderly. The majority of patients presented with a rash, but arthralgia and cytopenias were also reported.
Do not take proton pump inhibitors for longer than medically indicated. If a patient taking this drug develops symptoms or signs consistent with cutaneous lupus erythematosus or systemic lupus erythematosus, stop taking the drug and refer the patient to an appropriate specialist for evaluation. Most patients improved simply by discontinuing proton pump inhibitors within 4 to 12 weeks. Serological tests (e.g., antinuclear antibody (ANA)) may be positive, and high serological test results may take longer to resolve than clinical symptoms.
24) Fundic gland polyps: The use of proton pump inhibitors is associated with an increased risk of fundic gland polyps, especially when used for a year or more. Among patients using proton pump inhibitors, most patients who developed gastric fundic polyps were asymptomatic and discovered accidentally through endoscopy. Proton pump inhibitors should be used for the shortest period of time according to the symptoms being treated.
25) Acute interstitial renal tubulitis: Acute interstitial renal tubulitis has been observed in patients receiving medications containing esomeprazole and naproxen, and may occur at any time during treatment with this drug. Acute interstitial renal tubulitis may progress to renal failure. Patients suspected of having acute interstitial renal tubulitis should discontinue treatment with this drug and promptly take appropriate measures.
6. Drug interactions
1) Antiretroviral drugs:
① Atazanavir: When omeprazole (20 mg administered once daily) and atazanavir 300 mg/ritonavir 100 mg were coadministered to healthy volunteers, the exposure to atazanavir decreased (AUC, Cmax, and Cmin decreased by approximately 75%). Administration of atazanavir 400 mg four times daily cannot offset the effect of omeprazole on atanazavir exposure. Therefore, it should not be administered together with this drug.
② Nelfinavir: When co-administered with omeprazole (40 mg per day), the average AUC, Cmax, and Cmin of nelfinavir decreased by 36 to 39%. The average AUC, Cmax, and Cmin of the active metabolite M8 (hydroxy-t-butylamide) decreased by 75-92%. Therefore, it should not be administered together with this drug.
③ Saquinavir: When co-administered with omeprazole (40 mg per day), the blood concentration of saquinavir may increase and the risk of adverse reactions may increase. Therefore, administer with caution, such as reducing the dose according to the patient's individual condition.
2) Other non-steroidal anti-inflammatory drugs (NSAIDs), including COX-2 selective inhibitors: Do not use together with naproxen derivatives because the risk of adverse reactions such as gastrointestinal ulcers and bleeding may increase.
3) Hydantoin antiepileptic drugs, sulfa drugs, and sulfonylurea hypoglycemic agents: When administered together with these drugs, their action may be enhanced, so observe carefully and administer carefully.
4) Propranolol and other β-blockers: Co-administration with this drug may reduce the antihypertensive effect.
5) ACE inhibitors (captopril, etc.)/Angiotensin II receptor antagonists
There are reports that non-steroidal anti-inflammatory drugs may attenuate the antihypertensive effects of ACE inhibitors and angiotensin II receptor antagonists. NSAIDs may also increase the risk of renal impairment associated with the use of ACE inhibitors or angiotensin II receptor antagonists. Caution is required when coadministering nonsteroidal anti-inflammatory drugs and ACE inhibitors or angiotensin II receptor antagonists in the elderly, patients with hypovolemia, or renal impairment.
6) Loop diuretics and thiazide diuretics
① As a result of clinical trials and post-marketing surveillance, it was confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some patients due to this drug's inhibition of prostaglandin synthesis in the kidneys. Patients should be closely monitored for signs of renal failure during concurrent use of these drugs and nonsteroidal anti-inflammatory drugs.
② This drug may reduce the action of loop diuretics (furosemide, piretanide) and thiazide diuretics, so administer with caution when administered together.
7) Probenecid: When co-administered, the blood concentration of this drug increases and the half-life in the blood is prolonged, so administer with caution, including reducing the dose.
8) Aspirin: There is no consistent evidence that combined use with aspirin can reduce the risk of serious cardiovascular thrombotic events associated with the use of nonsteroidal anti-inflammatory drugs. As with other non-steroidal anti-inflammatory drugs, the combined use of this drug and aspirin may increase the risk of serious gastrointestinal adverse reactions, so the combined use of the two drugs is generally not recommended.
Clinical pharmacodynamic information suggests that coadministration of aspirin and naproxen for more than two consecutive days may inhibit the effects of low-dose aspirin on platelet activity, which may persist for up to several days after naproxen treatment is discontinued. The clinical relevance of this interaction is unknown.
9) Lithium: Non-steroidal anti-inflammatory drugs can increase serum lithium concentration and reduce renal clearance of lithium by inhibiting prostaglandin synthesis in the kidney. Co-administration of non-steroidal anti-inflammatory analgesics and lithium may cause lithium poisoning, so when used together, lithium must be administered with caution, including carefully observing signs of toxicity and reducing the dosage.
10) Methotrexate
Increased methotrexate levels have been reported in some patients when administered with proton pump inhibitors. Co-administration with non-steroidal anti-inflammatory drugs (NSAIDs) delays the excretion of methotrexate from the renal tubules, which may increase the fatal hematological toxicity of methotrexate. Therefore, it should not be administered in combination with high-dose methotrexate used in anticancer therapy, and must be administered with caution when administered in combination with low-dose methotrexate.
11) Coumarin-based anticoagulants (warfarin, etc.)
(1) For gastrointestinal bleeding, warfarin and non-steroidal anti-inflammatory drugs may have a synergistic effect, so patients who use both drugs together may have an increased risk of severe gastrointestinal bleeding compared to those who take the two drugs alone.
(2) When coadministered with coumarin-based anticoagulants, its action may be enhanced, so observe carefully and administer carefully.
12) Zidovudine: It may inhibit the metabolism of zidovudine and increase its blood concentration, so when used together, administer with caution, such as reducing the dose.
13) New quinolone antibiotics (enoxacin, etc.): Administer with caution as concurrent use with this drug may cause convulsions.
14) Cyclosporine and tacrolimus: When administered together with esomeprazole, the blood concentration of tacrolimus may increase. There is a risk of nephrotoxicity when NSAIDs and cyclosporine or tacrolimus are coadministered.
15) Selective serotonin reuptake inhibitors (SSRIs): Co-administration of NSAIDs, including COX-2 selective inhibitors, and SSRIs increases the risk of gastrointestinal bleeding.
16) Corticosteroids: When NSAIDs, including COX-2 selective inhibitors, are administered together with corticosteroids, the risk of gastrointestinal bleeding increases.
17) Cholestyramine: Absorption may be delayed when administered in combination with non-steroidal anti-inflammatory painkillers, including naproxen.
18) When administered in combination with cardiac glycosides such as digoxin, NSAIDs may increase the plasma concentration of cardiac glycosides. Additionally, when digoxin and omeprazole (20 mg per day) were co-administered in healthy patients, the bioavailability of digoxin increased by up to 10% (from 2 out of 10 to 30%).
19) Clopidogrel: From the results of studies in healthy volunteers, clopidogrel (initial dose 300 mg/maintenance dose 75 mg daily) and esomeprazole (orally administered 40 mg daily) appear to have a pharmacokinetic/pharmacodynamic interaction, which appears to reduce platelet aggregation by an average of 14% and reduces exposure to the active metabolite of clopidogrel by an average of 40%. appeared. Based on these results, esomeprazole and clopidogrel should not be administered together.
20) Drugs whose absorption is affected by gastric acidity: The absorption of drugs whose absorption mechanism is affected by gastric acidity may increase or decrease due to the decrease in gastric acidity during administration of this drug. As with other acid secretion suppressants and antacids, the absorption of ketoconazole and itraconazole may be reduced during administration of this drug.
21) CYP2C19, CYP3A4 inhibitors/inducers and substrates
Esomeprazole is metabolized by CYP2C19 and CYP3A4. It also inhibits CYP2C19, the main metabolic enzyme.
(1) When used together with drugs metabolized by CYP2C19, such as diazepam, citalopram, imipramine, clomipramine, phenytoin, warfarin, etc., the plasma concentration of these drugs may increase, so a dose reduction of these drugs may be necessary. Co-administration of 30 mg of diazepam, a CYP2C19 substrate, and esomeprazole reduced the clearance of diazepam by 45%.
(2) Co-administration of phenytoin and esomeprazole 40 mg to epilepsy patients increased the minimum plasma concentration of phenytoin by 13%. Monitor phenytoin plasma concentrations when starting or discontinuing treatment with this drug.
(3) Omeprazole (40 mg administered once daily) increased the Cmax and AUCτ of voriconazole (CYP2C19 substrate) by 15% and 41%, respectively.
(4) When esomeprazole and clarithromycin (500 mg administered twice daily), a CYP3A4 inhibitor, are administered simultaneously, the AUC of esomeprazole is doubled.
(5) Drugs known to be CYP2C19 and/or CYP3A4 inducers (e.g., rifampicin, St. John's wort) may decrease esomeprazole blood concentrations by increasing esomeprazole metabolism.
22) Cilostazol: In a crossover study in which 40 mg of omeprazole was administered to healthy patients, cilostazol Cmax and AUC increased by 18% and 26%, respectively. Among the active metabolites, 3,4-dihydrocilostazol increased Cmax and AUC by 29% and 69%, respectively.
23) Rilpivirine: When this drug and rilpivirine are used together, the plasma concentration of rilpivirine may decrease (increased gastric pH), so co-administration should not be performed. This may reduce the therapeutic effect of rilpivirine.
7. Administration to pregnant and lactating women
1) Fertility: Non-steroidal anti-inflammatory drugs such as naproxen can impair female fertility. Animal experiments have shown that non-steroidal anti-inflammatory drugs such as naproxen can suppress ovulation. Women who have difficulty conceiving or who are being investigated for infertility should consider discontinuing treatment with nonsteroidal anti-inflammatory drugs, including this drug.
2) Pregnant women: There are no well-controlled clinical data on the administration of this drug to pregnant women. Regarding naproxen, this drug should not be administered in the last trimester of pregnancy.
① Naproxen: In animal tests, naproxen did not show any direct or indirect harm related to embryo-fetal development. Epidemiological data from human studies have shown that the use of non-steroidal anti-inflammatory drugs during early pregnancy may increase the risk of miscarriage. Congenital malformations associated with NSAID administration have been reported in humans, but the frequency was low and there was no clear trend. As with other drugs of the same type, naproxen has been reported to cause delayed labor, increased incidence of dystocia, and reduced survival rate of offspring in animal experiments (pre- and postnatal period). When administered at the end of pregnancy, contraction of the ductus arteriosus in the fetus was observed. It also affected the cardiovascular system, including premature occlusion of the ductus arteriosus in the human fetus. Therefore, naproxen should not be administered during the third trimester of pregnancy. Use of non-steroidal anti-inflammatory drugs after 20 weeks of pregnancy can cause abnormalities in renal function in the fetus, resulting in oligohydramnios and, in some cases, neonatal renal failure. Ultrasound monitoring of amniotic fluid volume is considered in pregnant women who require administration of this drug. Nonsteroidal anti-inflammatory drugs should be administered to women planning to become pregnant or in the first or second trimester of pregnancy only when the potential benefit to the patient outweighs the potential risk to the fetus. When using this drug, it should be administered at the lowest dose and shortest treatment period. It is not recommended to use naproxen-containing preparations during labor or delivery because naproxen may adversely affect fetal circulation through its action of inhibiting prostaglandin synthesis and may inhibit contractions by increasing the bleeding tendency for both mother and fetus.
② Esomeprazole: Clinical data on the administration of esomeprazole to pregnant women is limited. Animal testing of esomeprazole did not show direct or indirect harmful effects on embryo-fetal development. Animal tests on the racemic mixture did not show direct or indirect harmful effects on pregnancy, parturition, or postnatal development. Nevertheless, caution should be exercised when administering this drug to pregnant women.
3) Nursing mothers: Naproxen in this drug is transferred to breast milk and causes adverse reactions that inhibit prostaglandin synthesis in newborns, so it should not be administered to nursing mothers.
8. Administration to children
Administration is not recommended for children under 18 years of age because safety and effectiveness have not been established.
9. Administration to elderly people
In general, elderly people are more prone to gastrointestinal ulcers and bleeding caused by anti-inflammatory painkillers, so they should be administered in the minimum necessary amount and administered carefully while observing the patient's condition, paying particular attention to the occurrence of adverse reactions, or consider administering other alternative medications.
10. Effect on clinical test values
1) Be careful when measuring bleeding time as it may inhibit platelet aggregation and prolong bleeding time.
2) Because it affects the measurement of 17-ketogenic steroids, discontinue administration of this drug 72 hours before measurement.
3) Naproxen may affect urine analysis of 5-hydroxy indole acetic acid (5HIAA).
4) The decrease in gastric acidity caused by the administration of this drug increases the concentration of serum chromogranin A (CgA). Therefore, people taking this drug may experience false positive results in neuroendocrine tumor diagnostic tests. Administration of this drug should be temporarily discontinued at least 14 days before the CgA test. If the test value exceeds the upper reference limit, retesting should be considered. When tests are performed repeatedly (e.g., monitoring), concentration measurements should be performed in the same laboratory because reference ranges differ between laboratories.
11. Treatment in case of overdose
There is no clinical trial data on overdose of this drug. The effects of overdose of this drug are expected to primarily reflect the effects of overdose of naproxen.
1) Symptoms
① Overdosage of naproxen may cause lethargy, dizziness, drowsiness, epigastric pain, abdominal discomfort, heartburn, indigestion, nausea, temporary worsening of liver function, hypoprothrombinemia, abnormal renal function, metabolic acidosis, apnea, disorientation, vomiting, gastrointestinal bleeding, hypertension, acute renal failure, respiratory depression, coma, and anaphylactoid reaction. You can.
② Symptoms associated with planned esomeprazole overdose (limited experience exceeding 240 mg of esomeprazole per day) were temporary. When taking 280 mg of this drug, gastrointestinal symptoms and weakness appeared. There were no significant problems when 80 mg of this drug was administered once.
2) Measures in case of overdose
There is no known specific antidote for naproxen and esomeprazole. Neither component is dialyzed. Therefore, symptomatic treatment and general maintenance treatment, such as gastric lavage and medicinal charcoal to reduce plasma concentration, should be used.
12. Precautions for application
1) This medicine consists of an immediate-release layer of esomeprazole, which dissolves in the stomach, and an enteric layer of naproxen, which dissolves in the small intestine. When administering, do not split, chew, or crush, but swallow it as is with water.
2) When taking this medicine after a meal, the absorption rate of esomeprazole in the body is reduced, so take it 30 minutes before a meal.
13. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
14. Pharmaceutical equivalence test information
A. Esomeprazole
The test drug Nasopra Tablet 500/20 mg [KyungDong Pharm Co., Ltd.] and the reference drug Vimobojeong 500/20 mg [LG Chemical Co., Ltd.] were administered orally once on an empty stomach to 47 healthy adults in a 2×4 cross-over test to measure esomeprazole in the blood. When the comparative evaluation item values (AUCt, Cmax) were log-transformed and subjected to statistical processing, the difference in average values was found to be The 90% confidence interval was within the equivalence standard, demonstrating biological equivalence.
※ Table: Refer to attached document
B. Naproxen
The test drug Nasopra Tablet 500/20 mg [KyungDong Pharm Co., Ltd.] and the reference drug Bimobojeong 500/20 mg [LG Chemical Co., Ltd.] were orally administered to healthy adults as a single tablet each on an empty stomach and after a meal in a 2×2 cross-over study. Naproxen in the blood of 50 people (fasting) and 53 people (after a meal) was measured, and comparative evaluation items (AUCt, Cmax) were obtained. When log transformed and subjected to statistical processing, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.
<empty stomach>
※ Table: Refer to attached document
<After meal>
※ Table: Refer to attached document
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Period of use
24 months from date of manufacture